Innovative RapifleX MALDI-TOF/TOF showcased by Bruker

At the 64th ASMS Conference, Bruker introduces rapifleX, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.

The rapifleX is by far the most advanced TOF/TOF system today, and was re-designed from the ground up to meet today’s highest demands for in-depth intact and top-down protein characterization, and high-performance, high-throughput mass spectrometry imaging (MSI).

With its next-generation TOF/TOF ion optics and smartbeam® 10 kHz proprietary laser technology, the rapifleX system now offers significantly higher speed, better mass resolution and mass accuracy, and a significantly enhanced MS/MS mass range to enable new research and routine applications.

Its unprecedented 10 kHz speed and ion source robustness, its wide dynamic range, higher specificity and resolution all contribute to the detailed characterization of biologically and clinically relevant lipids, peptides and proteins, resetting customer MALDI-TOF/TOF expectations for in-depth protein characterization and imaging of tissues, cell cultures, or other applications.  Its enhanced ease-of-use, robustness and stability make the rapifleX a game-changer for research and large-scale validation.

Dr. Julian D. Langer, at the Max-Planck Institute (MPI) of Biophysics and the MPI for Brain Research in Frankfurt am Main, Germany, stated:  “In our lab, with its high MS2 isolation efficiency, resolution and mass accuracy at high m/z values, the rapifleX TOF/TOF has been instrumental in identifying and characterizing new subunits of membrane protein complexes, including prokaryotic respiratory chain complexes and antibiotic drug targets.”

The rapifleX TOF/TOF is well-suited for detailed protein characterization in life science research and biopharmaceutical laboratories.  Many protein characterization tasks can be improved to gain better biological insight, including

  • fast identification of post-translational modifications (PTM),
  • top-down protein sequencing,
  • patented T³-Sequencing to identify or confirm suspected modifications or sequence alterations near protein N- or C-termini,
  • automated disulfide analysis of intact proteins without a priori assumptions using Bruker’s unique DisulfideDetect™ method and software, and
  • disulfide scrambling and trisulfide analysis with simplicity, speed and dynamic range.

Tissue- and cell-type specific proteomics is a major advancement for relevant biomarker discovery and identification, and requires MALDI imaging studies which include the identification of detected biomarker candidates for validation and subsequent development of targeted assays.

The rapifleX extends the MALDI Tissuetyper® imaging capabilities with rapid, spatially resolved MS/MS data.  It supports the patented ImageID™ workflow for biomarker discovery in MALDI imaging cohort studies, by obtaining matching identifications of tryptic peptides by LC-MALDI-TOF/TOF analysis.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker Daltonics. (2019, June 19). Innovative RapifleX MALDI-TOF/TOF showcased by Bruker. News-Medical. Retrieved on August 12, 2022 from

  • MLA

    Bruker Daltonics. "Innovative RapifleX MALDI-TOF/TOF showcased by Bruker". News-Medical. 12 August 2022. <>.

  • Chicago

    Bruker Daltonics. "Innovative RapifleX MALDI-TOF/TOF showcased by Bruker". News-Medical. (accessed August 12, 2022).

  • Harvard

    Bruker Daltonics. 2019. Innovative RapifleX MALDI-TOF/TOF showcased by Bruker. News-Medical, viewed 12 August 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Exploring the Relationship Between Mass Spectrometry and Informatics